IL-33 drives the antitumor effects of dendritic cells via the induction of Tc9 cells
作者机构：Department of Gynecological OncologyThe First Hospital of Jilin UniversityChangchun 130061China Department of Cancer ImmunologyThe First Hospital of Jilin UniversityChangchun 130061China Department of Rheumatology and ImmunologyChina-Japan Union Hospital of Jilin UniversityChangchun 130033China Department of HematologyThe First Hospital of Jilin UniversityChangchun 130061China and 5 Department of Cancer BiologyLerner Research InstituteCleveland ClinicClevelandOH 44195USA
出 版 物：《Cellular & Molecular Immunology》 (中国免疫学杂志（英文版）)
年 卷 期：2019年第16卷第7期
页 面：644-651页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：funds from National Natural Science Foundation of China(81372536 to S.W. 81502452 to X.C.and 81602485 to Y.Z.)
主 题：Interleukin-33 Dendritic cells Tc9 Cancer immunology
摘 要：Dendritic cell(DC)tumor vaccines exert their antitumor effects through the induction of effector T *** recently identified Tc9 cells as a new potent antitumor effector T cell ***,approaches to direct DCs to preferably prime antitumor Tc9 cells should be further ***,we demonstrate that the addition of interleukin(IL)-33 potently promotes the induction of Tc9 cells by DCs in vitro and in ***-33 treatment also drives the cytotoxic activities of DC-induced Tc9 ***,IL-33 treatment enhances cell survival and proliferation of DC-primed CD8+T *** importantly,the addition of IL-33 during in vitro priming of tumor-specific Tc9 cells by DCs increases the antitumor capability of Tc9 *** studies demonstrated that IL-33 treatment inhibits exhaustive CD8+T cell differentiation by inhibiting PD-1 and 2B4 expression and increasing IL-2 and CD127(IL-7 receptor-α,IL-7Rα)expression in CD8+T ***,the addition of IL-33 further promotes the therapeutic efficacy of DC-based tumor vaccines in the OT-I mouse *** study demonstrates the important role of IL-33 in DC-induced Tc9 cell differentiation and antitumor immunity and may have important clinical implications.
维普期刊数据库